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INTRODUCTION
Postnatal rubella is a mild illness, a disease which was considered to be of only
minor importance for many years. The first authors to write about the disease as
distinct from other exanthemata were German physicians; they differentiated
rubella from measles and scarlet fever in the latter part of the eighteenth century
and called the disease Rotheln. Hence the common English language eponym is
'German measles'. Some consider that the term 'German' in German measles is
probably of literary rather than of geographical significance and that it came from
the old French 'germain' (derived from the Latin 'germanus'), meaning 'closely
akin to ' measles [1]. That it is not generally called by its German name, Rotheln,
is due to Veale, a Scottish physician who in 1866 described 30 cases of rubella in
the Edinburgh Medical Journal, and proposed 'rubella' as a short and euphonius
name that could be easily pronounced [2].
Epidemics of rubella have been described in Europe and in the United States
since the nineteenth century. A pandemic of rubella started in Europe in the early
1960s and it spread to the United States in the next several years. As a result,
thousands of pregnancies were affected, leaving behind a wake of abnormal infants
and terminated pregnancies [3]. The pandemic led to better understanding of the
constellation of the disease caused by rubella infection during pregnancy. An
expanded congenital rubella syndrome was recognized, adding to the already
known rubella triad hepatitis, splenomegaly, thrombocytopenia, encephalitis,
mental retardation and multiple other anomalies. The pandemic also made it
obvious that a vaccine was urgently needed [4].
Between 1965 and 1967, several attenuated rubella strains were developed in
the USA and rubella vaccine was introduced in the USA in 1969 and in the UK
in 1970.
PLAN FOR ELIMINATION OF CONGENITAL RUBELLA SYNDROME IN EUROPE
In 1984, the WHO Regional Committee for Europe set as one of the targets the
elimination of congenital rubella from the Region by the year 2000. Other targets
were elimination of indigenous measles, poliomyelitis, neonatal tetanus, and
diphtheria. Recommendations on the work required to attain this target were put
forward at the Second Conference on Immunization Policies in Europe, in Karlovy
Vary, Czechoslovakia in December 1984 [5]. According to these recommendations,
by 1990 all European countries should be using rubella vaccine in their national
programmes, by 1995 all European countries should have achieved rubella vaccine
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coverage of at least 90% of the target population and established effective
surveillance and investigation systems, and by 1996 all European countries should
be investigating every suspected case of congenital rubella syndrome (CRS).
The current status of CRS elimination varies considerably in different European
countries. Some countries have well-organized preventive programmes and others
have no coherent policy for controlling rubella. If the goal of elimination of CRS
from Europe by the year 2000 is to be achieved, it is vital that all countries in the
Region strengthen their immunization programmes against rubella and set up
effective surveillance systems.
CURRENT STATUS OF RUBELLA
Trends in incidence. Surveillance on the incidence of rubella and CRS was very
poor in most European countries before 1985. It started to improve along with
the introduction of MMR vaccine. At the beginning of the 1970s rubella was a
notified disease in only eight European countries [6]. In 1990, rubella is a notifiable
disease in 24 of 32 countries (75%) in the WHO European Region. Eight countries
do not report rubella cases, including Germany and France. Congenital rubella
syndrome is reported (separately from rubella) in only 13 (41 %) European
countries [7]. The number of reported CRS cases ranged from 0 to 88 between 1985
and 1987 [8]. The completeness of the reporting of rubella in Europe is still low and
the magnitude of under reporting is large. Although existing surveillance data
cannot be considered qualitatively accurate, it is useful to depict the trends and
patterns of rubella occurrence.
In the prevaccine era, minor epidemics of rubella occurred in the USA every 6-9
years; major epidemics occurred at intervals ranging from 10 to 30 years. Many
European countries, however, reported a more frequent occurrence of rubella
epidemics in the prevaccine era. Fairly intensive epidemics occurred at 4-year
intervals in Czechoslovakia, Hungary, Poland and Yugoslavia. In the UK, the
pattern was more irregular, with an interval of 8—9 years between major epidemics
and with less regular epidemics in the intervening years [9]. Epidemic waves
continue to be reported every 4-5 years in countries which did not implement
routine rubella immunization programmes in young children (Fig. la). The
epidemics built up and receded over 3 to 4-year intervals. In countries, that
implemented routine rubella immunization programmes for young children, a
downward trend in rubella incidence is clearly seen after 1985 (Fig. 16).
Age distribution of immunity against rubella
Because a significant proportion of rubella infection is subclinical, serological
surveys are essential in further delineating the epidemiology of rubella. The
rubella antibody profile of a population is related to age-specific rubella incidence.
Before the introduction of rubella vaccine in European countries, the percentage
of immune individuals increased steadily with age; approximately 50% of
children had rubella antibody by the age of 6-8 years (Fig. 2). More than 80% of
population had rubella antibody by 17-22 years and the percentage remained
relatively stable thereafter [13-20]. It should be stressed that from 5 to 20% of
persons between 15 and 35 years of age remain seronegative and susceptible to
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Fig. 1. Reported rubella incidence per 100000 population in several European
countries. 1981-9. (a) Countries with no routine immunization against rubella in young
children: -\ (-, Romania; X — X. Poland; •£—#•, Bulgaria; O—O, Italy, (b)
Countries with routine immunization against rubella in young children: •—«.
Finland; H h. Denmark; -J)t—j)k. Czechoslovakia; O—O, The Netherlands;
X — X. Norway.
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Fig. 2. Percentage of sera with antibodies against rubella by age groups in several
European countries, 1965-83 (according to Kantoch & Imbs [10], Lundstrom and
colleagues [11], Mihneva and colleagues [12], Toth [13] and WHO [9]). (a) O—O,
USSR 1971; X —X. Germany 1971; ^ —%, Sweden 1965 (females). (&) •£—^,
Poland 1982 (females); X —X, Bulgaria 1971-83 (females); O—O, Hungary 1967.
infection. In some countries (Poland, Bulgaria), the rate that immunity to rubella
was acquired seemed more rapid than in other countries (Hungary, Sweden) (Fig.
2. Table 1). In the USSR, the immunity status varied in different areas; the
development of more than 85 % level of immunity against rubella was completed
by 18-22 years in Moscow, by 13-14 years in the Armenian and Georgian republics
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Fig. 3. Percentage of sera with antibodies against rubella in England, 1988 and in
Finland. 1986 (according to Morgan-Capner and colleagues [25] and Ukkonen and
colleagues [20]). (as) England 1988: O—O, females; 4£—Jfi. males, (b) Finland 1986:
O—O, females; -J(t—^, males.
and by 10 years in the Kirghiz republic [24]. Within a particular country, the
pattern of rubella immunity appears to be stable over a long period of time
(Poland 1969 and 1982, Table 1). Rubella immunity has been found to be acquired
more slowly than immunity against measles, mumps and Epstein-Barr virus
[25, 26].
The introduction of rubella vaccine significantly changed the pattern of
immunity. In the UK, where rubella vaccine was used in prepubertal girls and
non-immune women, the proportions of subjects who have rubella antibody were
significantly higher in females than in males in age groups between 10 and 30,
reflecting the effect of selective rubella vaccination of girls and women (Fig. 3).
The effect of vaccination of 13-year-old girls is also seen in Finland when the
immunity against males and females is analyzed separately (Fig. 3).
The vaccination of children with MMR vaccine resulted in a significant increase
of rubella immunity among children. In Finland, before the introduction of MMR
vaccine, the percentage of immune individuals increased steadily, reaching a
plateau level of 90% by 17 years. MMR vaccine was introduced in 1982, and in
1986 about 95% immunity was achieved by the age of 2-3 years (Figs. 3, 4).
Age distribution of infection
The age specific infection pattern of rubella in the prevaccine era was quite
distinct from that of measles. Whereas measles infection rates were highest during
the first several years of life and decline to a negligible level by age 15, rubella
infection rates reached a peak later and continued through adolescence into young
adulthood [3].
In the prevaccine era, rubella was a childhood disease with the highest incidence
rates in the 5-14 years age group. Incidence rates increased slowly among children
of age 0-4 years, rose more steeply among children age 5-14 years, and then slowly
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268800048664
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 14:44:27, subject to the Cambridge Core terms of use, available at
15 20
Age (years)
30 2 4 6 8 10 15 20
Age (years)
25 30
Fig. 4. Occurrence of rubella IgG antibodies in sera and rubella infections in different
age groups, Finland 1980 and 1986 (according to Ukkonen and colleagues [20]). (a)
Rubella antibodies: ^—-fc, 1980; O—O. 1986. (b) Rubella infections: -fc—fc, 1980;
O—O, 1986.
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Fig. 5. Percentage distribution of rubella cases reported in 84 selected districts by age
groups and urban-rural status, Poland. 1967-74 (according to Rudnicka [27]). • .
Urban areas; ^ , rural areas.
decreased. A similar pattern was observed in Finland before the introduction of
MMR vaccination in young children (Fig. 4). The age-specific pattern of rubella
incidence differed between urban and rural areas. Data from Poland showed that
the highest rate in urban areas was reported for 5- to 9-year-old children, while in
rural areas the highest rate was shifted to the 10-14 years age group [27] (Fig. 5).
There is some evidence to suggest that the age-specific pattern of rubella is
changing in countries which have implemented routine immunization schedules
for children. In Finland, after the introduction of MMR vaccine in 1982 among
children of 14-18 months and 6 years old. the occurrence of rubella cases shifted
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to higher ages, peaking between 12 and 17 years of age. In 1986, no rubella cases
were found in children covered by MMR vaccination in the 2-10 years age group
(Fig. 4). The changes in incidence were correlated with the changes in the age-
specific immunity [20].
VACCINATION AGAINST RUBELLA
Strategies for vaccination
The primary aim of rubella immunization is to prevent congenital rubella
syndrome. Congenital rubella is a preventable disease provided vaccination
programmes are carefully planned and implemented. There are three main
approaches which have been applied in the USA, the UK and Sweden (Table 2).
The first approach has been used in the USA. This approach starts with mass
vaccination of children under the age of 12 years and is followed by routine
vaccination of children of both sexes when they reach one year of age. This
approach is intended to interrupt transmission of rubella virus among young
children (the primary transmission group), thus reducing the possibility of
exposure of a susceptible pregnant woman [29]. This strategy requires a high
immunization coverage of children at 15 months of age with combined MMR
vaccine. The attainment of very high levels of vaccination coverage in pre-school
children (> 90%) is, in part, a consequence of the USA school immunization law,
which require documentary evidence of immunization against certain common
vaccine-preventable diseases prior to school entry.
The second approach was undertaken until 1988 in the United Kingdom, and
is used in some European countries. This approach is a selective policy to
vaccinate prepubertal girls and non-immune women either before or after
pregnancy with one dose of monovalent rubella vaccine. This strategy aims to
protect individuals, but not to diminish the natural circulation of the wild virus.
Neither the reduction of natural rubella, nor the development of herd immunity
is part of the strategy; indeed the continued circulation of rubella virus was
considered a necessary contribution to maintaining the level of immunity in
women of child-bearing age [30].
The third approach has been implemented in Sweden. In 1980, the Swedish
Paediatric Association recommended a two-dose schedule using a combined MMR
vaccine and the programme was introduced in January 1982. Vaccination is
optional and is offered free of charge to children at 18 months (at child health
centres) and at 12 years (at school health centres). The ultimate aim of this
approach is the elimination of rubella as well as measles and mumps. The second
dose is given irrespective of history of disease or vaccination. This serves to
prevent the build-up of a susceptible population in older age-groups [31]. It is
expected that the second dose of MMR will immunize those not vaccinated at 18
months and those who failed to respond to the first dose of vaccine; it will also
provide a booster for children with low antibody titres [32].
The programme appears to have been successfully implemented; in 1985 MMR
coverage of preschool children and 12-year-old children in Sweden was about 90%
[33]. Continuous studies on epidemiology and immunity against three diseases will
be necessary to assess the effectiveness of this approach.
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Table 2. Comparison of three vaccination programmes to prevent congenital rubella
(according to Dudgeon, 1983 [28])
Prototype
country
USA
Objective
Break in transmission:
control of reservoir and
eradication of disease
Vaccine schedule
One dose of MMR
UK Selective immunization
Protection of the
individual
One dose of mono-
valent rubella
Sweden Eradication of rubella
in 10 vears
Two doses of MMR
Target groups
(a) all children
at 15 months
(b) adolescent and
adult 'susceptible'
females
(c) educational and
health care
personnel
(a) all girls at 10-
14 years
(6) 'susceptible'
females
(c) educational and
health personnel
(d) postpartum
women
(a) all children at
18 months
(6) all children at
12 vears
Finland introduced a two-dose MMR schedule in November 1982 with doses
given to children at 14-18 months and 6 years [20]. Norway adopted two-dose
MMR schedule in 1983.
Immunization schedules used in Europe
There are three main immunization schedules used in European countries in
1990 (Table 3). Five countries (Denmark, Finland, the Netherlands, Norway and
Sweden) use the Swedish approach vaccinating children at a young age and again
at school age.
A second group of countries uses an approach combining both mass
immunization of young children and selective vaccination of girls at a later age.
A combined measles, mumps and rubella (MMR) vaccine is used for young
children and for older children in the first approach, and monovalent rubella
vaccine is used for selective vaccination of girls.
A third group of countries uses 'selective' vaccination of teenage girls without
MMR for young children.
The USSR has already decided to introduce immunization against rubella but
the implementation of the programme is delayed by the lack of the vaccine which
is not yet locally produced. Albania, Bulgaria and Romania would also like to use
MMR vaccine when available.
Choice of the strategy
Choice of the appropriate policy in any country should take into consideration
the age distribution of immunity and infection and administrative, regulatory, or
educational feasibility of achieving and sustaining a high vaccine coverage.
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Table 3. Schedules for rubella vaccination currently used in some European
countries (according to Mata and Wals [34] and Miller and Salisbury [35])
Vaccination schedule for
Country
Denmark
Finland
Netherlands
Norway
Sweden
Belgium
Czechoslovakia
France
Germany
Hungary
Ireland
Spain
Switzerland
UK
Yugoslavia
Austria
Bulgaria
Poland
Italy
First dose for
children of both
sexes
A
Antigens
MMR*
MMR
MMR
MMR
MMR
MMR
R
MMR or MR*
MMR
R or MR
MMR
MMR
MMR
MMR
MMR
Age
15 mo.
14-18 mo.
14 mo.
18 mo.
18 mo.
15 mo.
1-2 yr
15 mo.
15 mo.
14 mo.
15-24 mo.
15 mo.
15 mo.
1-2 yr
1-2 yr
Second
children
dose for
of both
sexes
A
r
Antigens
MMR
MMR
MMR
MMR
MMR
Age
11-12 yr
6 yr
9yr
12 vr
12 yr
Only
Antigens
R*
R
R
R
R or MR
R
R
R at school
R
R
R
R
R
N
girls
Age
11-12 yr
12 yr
11-13 yr
11-15 yr
ll-12yr
12-14 yr
11 yr
10-14 yr
10-14 yr
15-16 yr
12 yr
12-14 yr
*MMR, measles, mumps and rubella combined vaccine; MR, measles and rubella combined
vaccine; R, monovalent rubella vaccine.
Selective rubella vaccination has achieved a substantial reduction in incidence
of rubella infection in pregnancy and its inevitable sequelae of congenital rubella
syndrome. However, recent epidemiological evidence has shown that while rubella
virus continues to circulate among children there is the risk of infection to
pregnant women, even when only 3 % of them are non-immune. The number of
infections among the 2-3 % of pregnant women still susceptible remains
unacceptably high and there is no prospect of eliminating congenital rubella
syndrome with selective vaccination alone [30, 36]. Therefore, a selective strategy
has been gradually abandoned in favour of combined strategies that include mass
immunization of young children in addition to immunization of schoolgirls and
susceptible females. Such a strategy has been endorsed by the recent meeting of
national programme managers on the WHO Expanded Programme on Immun-
ization in St Vincent in Italy [37].
The introduction of mass immunization of young children against rubella
quickly reduces the circulation of rubella virus. This postpones the age of first
exposure among the unvaccinated to early adult life. These hazards are more
intrusive when vaccination is performed early and when children of both sexes are
vaccinated [38]. Replacing single-antigen measles vaccine with the triple-antigen
MMR vaccine in a large proportion of children (80 % or more) will rapidly reduce
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the circulation of rubella and thus the chance of infection of non-immune pregnant
women. However, it has been postulated, using predictions from mathematical
models, that if MMR vaccine coverage is less than 60-70%, infection in persons
who remain unvaccinated may be deferred until adult life; in the case of rubella
it has been suggested that this could result in a possible increase in congenital
rubella syndrome [39], Thus, an inadequately implemented childhood rubella
immunization policy could cause more damage than no rubella vaccination at all
[35]. In many European countries, the coverage with measles vaccine is still low
and it is important that coverage is increased before or when introducing MMR
vaccine. Several approaches have been suggested including introduction of
legislation requiring evidence of immunization for entry to school, increased
professional commitment toward vaccination and providing adequate funding for
local staff and adequate amounts of vaccine [30].
Monitoring the rubella control programme
It is important that any rubella control programme has built in monitoring
systems. Vaccine coverage of target age-groups should be monitored. MMR
vaccine has been introduced into the routine immunization schedules in 19
European countries. Data on vaccine coverage are incomplete but from the
information reported to the WHO, one may conclude that coverage rate of at least
80% in young children has been achieved in nine countries. Two countries
reported the coverage rate around 60% and data from the remaining eight
countries are not yet available [7, 40].
Surveillance systems should be developed and strengthened to monitor the
impact of the immunization programme. Countries without rubella control
programmes should assess the magnitude of congenital rubella infection by
estimating the frequency of rubella infections in pregnant women or by
determining by serosurveys the susceptibility and/or age-specific acquisition of
rubella antibody in postpubertal women. Countries with rubella control
programmes should monitor cases of acquired rubella, including CRS, and
prevalence of seropositivity in postpubertal females. Surveillance systems should
include monitoring rubella associated termination of pregnancies and investi-
gation of deafness in childhood. This will help to assess the effectiveness of the
programme and to determine high risk populations that should be targets of
intensified vaccination efforts [41]. In countries using MMR vaccine, measles,
mumps and rubella should all be notifiable diseases.
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